This article is more than 5 years old. Information may no longer be current.
Top 10 meeting news stories posted in 2018
Click Here to Manage Email Alerts
Endocrine Today has compiled a list of the top 10 meeting news reports posted in 2018. Healio.com/Endocrinology readers in 2018 were interested in essential oils disrupting endocrine function, semaglutide producing weight loss and the safety of an artificial pancreas.
Two common essential oils contain endocrine-disrupting chemicals — The Endocrine Society Annual Meeting
Certain chemical components of lavender and tea tree oils have been identified as endocrine-disrupting chemicals, and a new study lends further evidence to suggest that topical use in prepubescent boys may lead to the development of male prepubertal gynecomastia.
Semaglutide produces weight loss in adults with obesity, without diabetes — The Endocrine Society Annual Meeting
Nearly two-thirds of adults with obesity and without diabetes who received daily injections of the GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) decreased their body weight by at least 10% compared with about one-third of those taking liraglutide (Victoza and Saxenda, Novo Nordisk).
OBSERVE-4D: No amputation risk with canagliflozin in type 2 diabetes — American Diabetes Association Scientific Sessions
Adults with type 2 diabetes with and without established cardiovascular disease treated with the SGLT2 inhibitor canagliflozin (Invokana, Janssen) did not have an increased risk for below-the-knee amputation compared with patients assigned similar SGLT2 inhibitors or other antidiabetes therapies.
Artificial pancreas safe, effective in young children with type 1 diabetes — The Endocrine Society Annual Meeting
Children aged 7 to 13 years with type 1 diabetes who used an artificial pancreas system for 3 months experienced a reduction in HbA1c and an improvement in time to glucose values in the target range, without any episodes of severe hypoglycemia or diabetic ketoacidosis.
Effects of low sperm count go beyond fertility — T he Endocrine Society Annual Meeting
A total sperm count of less than 39 million per ejaculate may place men at increased risk for poorer metabolic, CV and bone health compared with men with higher total sperm counts.
Microbiome holds clues to success with personalized nutrition in diabetes — American Association of Diabetes Educators Annual Meeting
Postprandial glucose responses to specific foods vary from person to person depending on the makeup of his or her gut microbiome, underscoring a need for personalized nutrition to help better manage diabetes.
New diabetes technology options can ease disease management, but education key — American Association of Diabetes Educators Annual Meeting
Recent developments and approvals in the diabetes technology space have revolutionized care and glycemic management for type 1 and type 2 diabetes, but patients must be careful to avoid several key mistakes when using insulin pumps and continuous glucose monitoring.
Vitamin D supplementation associated with dose-response increase in hypercalciuria — American Society for Bone and Mineral Research Annual Meeting
Older adults assigned to a high dose of daily vitamin D supplementation were more likely to develop hypercalciuria over 3 years vs. those assigned to a lower daily dose of the supplement, with the condition resolving after reducing calcium intake, according to findings from the Calgary Vitamin D study.
Empagliflozin reduces liver fat in patients with type 2 diabetes, NAFLD — The Endocrine Society Annual Meeting
Empagliflozin (Jardiance, Boehringer Ingelheim/Lilly), an oral SGLT2 inhibitor, may provide substantial benefit to patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) by aiding in the reduction of liver fat, according to findings from the E-LIFT trial.
VIDEO: ‘Big year,’ breakthroughs seen in type 1 diabetes — The Endocrine Society Annual Meeting
In this video exclusive, Dawn Belt Davis, MD, PhD, associate professor in the division of endocrinology, diabetes and metabolism at the University of Wisconsin School of Medicine and Public Health in Madison, recaps some of the exciting developments in type 1 diabetes.